查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1890730

前列腺癌治療市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察與預測（2024-2032 年）

Prostate Cancer Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 請詢問到貨日

價格

前列腺癌治療市場成長驅動因素

隨著前列腺癌發病率的持續上升以及先進治療方案的日益普及，全球前列腺癌治療市場正在快速擴張。根據最新的產業評估，該市場在 2024 年的價值為 198.1 億美元，預計到 2025 年將達到 251.2 億美元。預計到 2032 年，該市場將飆升至 1,019.8 億美元，在預測期內實現 22.16% 的強勁複合年增長率 (CAGR)。這一快速成長反映了標靶治療、放射性藥物、免疫療法和新一代雄性激素受體抑制劑在全球的加速應用。

市場概況及區域領先地位

2024年，北美以50.98%的市場佔有率引領全球前列腺癌市場，這主要得益於其高發病率、完善的醫療基礎設施、早期治療的普及以及創新療法的廣泛應用。美國仍然是規模最大、最具影響力的市場，這主要歸功於前列腺癌發病率的上升、有利的醫療保險政策以及眾多製藥公司不斷推出突破性療法。

根據美國癌症協會統計，攝護腺癌主要影響老年男性，十分之六的病例發生在65歲及以上的人。確診時的中位年齡約為67歲，隨著全球老年人口的增長，治療需求呈指數級增長。諸如一年一度的 "Movember" （鬍鬚月）活動等提高公眾意識的活動，進一步促進了早期診斷和及時治療。

市場成長驅動因素

全球前列腺癌發生率的上升是主要的成長因素。根據 GLOBOCAN 2022 的數據，全球新增攝護腺癌病例約 147 萬例，攝護腺癌是全球第四大常見癌症。篩檢率的提高、公眾健康意識的增強以及診斷技術的進步，都促成了患者群體的成長。

技術進步也發揮關鍵作用。包括輝瑞、安斯泰來、強生、賽諾菲、阿斯特捷利康和艾伯維在內的主要製藥公司，持續投資下一代療法、聯合療法和個人化醫療。 PARP 抑制劑、雄性激素受體抑制劑和放射性配體療法的研發正在重塑治療指南，並有助於提高存活率。

市場限制因子

儘管成長前景強勁，但市場仍面臨挑戰。由於雄性激素受體突變導致的雄性激素剝奪療法抗藥性仍然是一個主要障礙，通常會導致去勢抵抗性前列腺癌 (CRPC)。此外，荷爾蒙療法和化療常見的副作用，例如性慾減退、潮熱、骨密度下降、疲勞和體重增加，會阻礙患者的依從性並影響治療的連續性。

先進療法的高昂費用也限制了其應用，尤其是在報銷有限的中低收入地區。複雜的治療方案和長期依從性要求也增加了整體醫療保健成本。

新興市場的機會

研發活動正在加速，尤其是在轉移性去勢抵抗性前列腺癌 (mCRPC) 的聯合治療領域。 PARP 抑制劑與荷爾蒙療法聯合使用已顯示出更高的療效，並正在獲得監管部門的批准。 2024年11月，拜耳的NUBEQA獲得FDA批准，可作為ADT聯合療法用於轉移性激素敏感性前列腺癌（mHSPC），這預示著聯合療法的應用前景將更加廣闊。

針對包括BRCA1和BRCA2在內的基因突變的創新療法正日益受到關注。例如，強生公司的AKEEGA於2023年獲準用於治療BRCA突變型轉移性去勢抵抗性攝護腺癌（mCRPC），這反映了精準癌症治療日益受到重視。

細分市場洞察

雄性激素受體抑制劑（ARI）將在2024年佔市場主導地位，市佔率高達73.1%，這主要得益於其作為晚期前列腺癌一線治療藥物的日益普及。

由於患者強烈偏好，口服給藥途徑將引領市場，預計到 2025 年將佔 86.7% 的市場佔有率。

依治療類型劃分，激素療法仍將佔主導地位，因為它能夠抑制雄激素依賴性腫瘤的生長。

依疾病狀態劃分，轉移性去勢抵抗性前列腺癌 (mCRPC) 佔最大佔有率，預計到 2025 年將佔 83.7% 的市場佔有率，這主要歸功於其高臨床需求以及靶向療法頻繁獲得監管部門批准。

區域展望

  • 北美：市場規模最大，預計到 2025 年將達到 123.2 億美元。
  • 歐洲：受益於強效藥物的供應和臨床進展，預計到 2025 年將達到 58.9 億美元。
  • 亞太地區：受癌症意識提高和腫瘤治療覆蓋範圍擴大的推動，預計到 2025 年將達到 44.8 億美元。
  • 拉丁美洲和中東：由於公眾意識提高和監管環境改善，預計將保持穩定成長。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 2024年主要國家及地區攝護腺癌盛行率
  • 主要公司產品線分析
  • 替代療法概述
  • 市場主要新創企業
  • 主要公司新產品發布
  • 主要產業趨勢（併購、合作等）
  • 新冠疫情的影響市場

第五章 全球前列腺癌治療市場分析、洞察與預測（2019-2032）

  • 市場分析、洞察與預測 - 依藥物類別劃分
    • 雄性激素受體抑制劑
    • 微管抑制劑
    • 促性腺激素釋放激素 (GnRH) 激動劑
    • 促性腺激素釋放激素 (GnRH) 受體拮抗劑
    • 其他
  • 市場分析、洞察與預測 - 依給藥途徑劃分
    • 口服
    • 腸外給藥
  • 市場分析、洞察與預測 - 依療法劃分
    • 化療
    • 荷爾蒙療法
    • 標靶治療治療
    • 免疫療法
  • 市場分析、洞察與預測 - 依疾病類型劃分
    • 轉移性去勢抵抗性攝護腺癌
    • 非轉移性去勢抵抗性攝護腺癌
  • 市場分析、洞察與預測 - 依分銷管道劃分
    • 醫院藥房
    • 藥局和零售藥房
    • 線上藥房
  • 市場分析、洞察與預測 - 依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美前列腺癌治療市場分析、洞察與預測，2019-2032

  • 依國家/地區
    • 美國
    • 加拿大

第七章：歐洲前列腺癌藥物市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞半島
    • 歐洲其他地區

第八章：亞太地區前列腺癌藥物市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 其他地區亞太地區

第九章 拉丁美洲前列腺癌治療市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章 中東與非洲前列腺癌治療市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 海灣合作委員會
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析（2024）
  • 公司公司簡介
    • 安斯泰來藥廠
    • 輝瑞公司
    • 強生服務公司
    • 賽諾菲
    • 費林製藥公司
    • 住友製藥株式會社（Myovant Sciences GmbH）
    • 艾伯維公司
    • 阿斯特捷利康
    • 托瑪公司
    • Dendreon Pharmaceuticals LLC
    • 拜耳股份公司
Product Code: FBI112008

Growth Factors of prostate cancer therapeutics Market

The global prostate cancer therapeutics market is expanding rapidly as the prevalence of prostate cancer continues to rise and advanced treatment options become more accessible. According to the latest industry assessment, the market was valued at USD 19.81 billion in 2024, is projected to reach USD 25.12 billion in 2025, and is expected to surge to USD 101.98 billion by 2032, registering a robust CAGR of 22.16% during the forecast period. The sharp increase reflects accelerated adoption of targeted therapies, radiopharmaceuticals, immunotherapies, and next-generation androgen receptor inhibitors worldwide.

Market Overview and Regional Leadership

In 2024, North America dominated the global market with a 50.98% share, driven by a high prostate cancer burden, strong healthcare infrastructure, early therapy adoption, and extensive availability of innovative treatment options. The U.S. remains the largest and most influential market owing to the rising incidence of prostate cancer, supportive reimbursement policies, and a strong presence of pharmaceutical companies introducing breakthrough therapies.

Prostate cancer predominantly affects older men, with 6 in 10 diagnoses occurring in individuals aged 65 and above, according to the American Cancer Society. The median age of diagnosis is around 67, and as the global geriatric population grows, treatment demand is increasing sharply. Rising awareness initiatives such as the annual Movember campaign further support early diagnosis and timely therapeutic intervention.

Market Growth Drivers

The rising global prevalence of prostate cancer is a major growth catalyst. GLOBOCAN 2022 reported approximately 1.47 million new cases, ranking prostate cancer as the fourth most prevalent cancer worldwide. Increased screening rates, public health awareness, and improved diagnostic technologies contribute to the expanding patient pool.

Technological advancements also play a key role. Pharmaceutical leaders including Pfizer, Astellas, Johnson & Johnson, Sanofi, AstraZeneca, and AbbVie are continually investing in next-generation therapies, combination regimens, and personalized medicine. The development of PARP inhibitors, androgen receptor inhibitors, and radioligand therapies is reshaping treatment guidelines and improving survival outcomes.

Market Restraints

Despite strong growth prospects, the market faces challenges. Resistance to androgen deprivation therapy-caused by androgen receptor mutations-remains a significant barrier, often leading to Castration-Resistant Prostate Cancer (CRPC). Additionally, common side effects of hormonal and chemotherapies, such as decreased libido, hot flashes, reduced bone density, fatigue, and weight gain, hinder patient adherence and impact treatment continuity.

The high cost of advanced therapies further restricts adoption, particularly in low- and middle-income regions where reimbursement systems are limited. Complex treatment regimens and long-term medication requirements also elevate overall healthcare expenditures.

Emerging Market Opportunities

Research and development activities are accelerating, particularly in the field of combination therapies for managing metastatic castration-resistant prostate cancer (mCRPC). PARP inhibitors combined with hormonal therapies are showing enhanced efficacy and gaining regulatory approval. In November 2024, Bayer's NUBEQA received FDA acceptance for use with ADT in metastatic hormone-sensitive prostate cancer (mHSPC), signaling expanding opportunities for combination regimens.

Innovative therapies targeting genetic mutations, including BRCA1 and BRCA2, are gaining traction. For example, Johnson & Johnson's AKEEGA, approved in 2023 for BRCA-mutated mCRPC, reflects the growing emphasis on precision oncology.

Segmental Insights

Androgen receptor inhibitors dominated the market in 2024 with a 73.1% share, supported by rising adoption for first-line treatment in advanced prostate cancer.

The oral route of administration led the market with strong patient preference and is set to capture 86.7% of the market in 2025.

By therapy, hormonal therapy remains the leading segment due to its effectiveness in controlling androgen-dependent tumor growth.

By disease state, mCRPC accounted for the dominant share, expected to capture 83.7% of the market in 2025, due to high clinical need and frequent regulatory approvals for targeted therapies.

Regional Outlook

  • North America: Strongest market; expected to reach USD 12.32 billion in 2025.
  • Europe: Projected to reach USD 5.89 billion in 2025, supported by strong drug availability and clinical advancements.
  • Asia Pacific: Expected to reach USD 4.48 billion in 2025, driven by increased cancer awareness and expanding access to oncology treatments.
  • Latin America & Middle East: Steady growth with increased awareness and improving regulatory landscapes.

Conclusion

With its market size rising from USD 19.81 billion in 2024 to a projected USD 101.98 billion by 2032, the prostate cancer therapeutics market is undergoing transformative expansion. The rapid integration of precision medicines, combination therapies, and immunotherapies-coupled with increasing disease prevalence-will continue to drive substantial growth through 2032.

Segmentation By Drug Class

  • Androgen Receptor Inhibitors
  • Microtubule Inhibitors
  • Gonadotropin Releasing Hormone (GnRH) Agonist
  • Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Therapy

  • Chemotherapy
  • Hormonal Therapy
  • Targeted therapy
  • Immunotherapy

By Disease State

  • Metastatic Castration-Resistant Prostate Cancer
  • Non-Metastatic Castration-Resistant Prostate Cancer

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2024
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. Overview of Alternative Therapies
  • 4.4. Key Start-ups in the Market
  • 4.5. New Product Launches, by Key Players
  • 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.7. Impact of COVID-19 on the Market

5. Global Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Androgen Receptor Inhibitors
    • 5.1.2. Microtubule Inhibitors
    • 5.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 5.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Therapy
    • 5.3.1. Chemotherapy
    • 5.3.2. Hormonal Therapy
    • 5.3.3. Targeted therapy
    • 5.3.4. Immunotherapy
  • 5.4. Market Analysis, Insights and Forecast - By Disease State
    • 5.4.1. Metastatic Castration-Resistant Prostate Cancer
    • 5.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Drug Stores & Retail Pharmacies
    • 5.5.3. Online Pharmacies
  • 5.6. Market Analysis, Insights and Forecast - Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Androgen Receptor Inhibitors
    • 6.1.2. Microtubule Inhibitors
    • 6.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 6.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Therapy
    • 6.3.1. Chemotherapy
    • 6.3.2. Hormonal Therapy
    • 6.3.3. Targeted therapy
    • 6.3.4. Immunotherapy
  • 6.4. Market Analysis, Insights and Forecast - By Disease State
    • 6.4.1. Metastatic Castration-Resistant Prostate Cancer
    • 6.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Drug Stores & Retail Pharmacies
    • 6.5.3. Online Pharmacies
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Androgen Receptor Inhibitors
    • 7.1.2. Microtubule Inhibitors
    • 7.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 7.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Therapy
    • 7.3.1. Chemotherapy
    • 7.3.2. Hormonal Therapy
    • 7.3.3. Targeted therapy
    • 7.3.4. Immunotherapy
  • 7.4. Market Analysis, Insights and Forecast - By Disease State
    • 7.4.1. Metastatic Castration-Resistant Prostate Cancer
    • 7.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Drug Stores & Retail Pharmacies
    • 7.5.3. Online Pharmacies
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.6.1. Germany
    • 7.6.2. U.K.
    • 7.6.3. France
    • 7.6.4. Italy
    • 7.6.5. Spain
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Androgen Receptor Inhibitors
    • 8.1.2. Microtubule Inhibitors
    • 8.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 8.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Therapy
    • 8.3.1. Chemotherapy
    • 8.3.2. Hormonal Therapy
    • 8.3.3. Targeted therapy
    • 8.3.4. Immunotherapy
  • 8.4. Market Analysis, Insights and Forecast - By Disease State
    • 8.4.1. Metastatic Castration-Resistant Prostate Cancer
    • 8.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Drug Stores & Retail Pharmacies
    • 8.5.3. Online Pharmacies
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Androgen Receptor Inhibitors
    • 9.1.2. Microtubule Inhibitors
    • 9.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 9.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Therapy
    • 9.3.1. Chemotherapy
    • 9.3.2. Hormonal Therapy
    • 9.3.3. Targeted therapy
    • 9.3.4. Immunotherapy
  • 9.4. Market Analysis, Insights and Forecast - By Disease State
    • 9.4.1. Metastatic Castration-Resistant Prostate Cancer
    • 9.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital Pharmacies
    • 9.5.2. Drug Stores & Retail Pharmacies
    • 9.5.3. Online Pharmacies
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Androgen Receptor Inhibitors
    • 10.1.2. Microtubule Inhibitors
    • 10.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 10.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Therapy
    • 10.3.1. Chemotherapy
    • 10.3.2. Hormonal Therapy
    • 10.3.3. Targeted therapy
    • 10.3.4. Immunotherapy
  • 10.4. Market Analysis, Insights and Forecast - By Disease State
    • 10.4.1. Metastatic Castration-Resistant Prostate Cancer
    • 10.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Drug Stores & Retail Pharmacies
    • 10.5.3. Online Pharmacies
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Astellas Pharma Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Pfizer Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Johnson & Johnson Services, Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Sanofi
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Ferring Pharmaceuticals Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Sumitomo Pharma Co., Ltd. (Myovant Sciences GmbH)
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. AbbVie Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. AstraZeneca
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Tolmar, Inc.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Dendreon Pharmaceuticals LLC.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. Bayer AG
      • 11.2.11.1. Overview
      • 11.2.11.2. Products
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 2: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 3: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2019-2032
  • Table 4: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
  • Table 5: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 6: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 7: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 8: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 9: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2019-2032
  • Table 10: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
  • Table 11: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 12: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 13: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 14: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 15: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2019-2032
  • Table 16: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
  • Table 17: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 18: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 19: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 20: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 21: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2019-2032
  • Table 22: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
  • Table 23: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 24: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 25: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 26: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 27: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2019-2032
  • Table 28: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
  • Table 29: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 30: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 31: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 32: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 33: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2019-2032
  • Table 34: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
  • Table 35: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 36: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Prostate Cancer Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024 & 2032
  • Figure 3: Global Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024 & 2032
  • Figure 4: Global Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024 & 2032
  • Figure 5: Global Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2024 & 2032
  • Figure 6: Global Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 7: Global Prostate Cancer Therapeutics Market Value (USD billion), by Region, 2024 & 2032
  • Figure 8: North America Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 9: North America Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024
  • Figure 10: North America Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 11: North America Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024
  • Figure 12: North America Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032
  • Figure 13: North America Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024
  • Figure 14: North America Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2024 & 2032
  • Figure 15: North America Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2024
  • Figure 16: North America Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 17: North America Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 18: North America Prostate Cancer Therapeutics Market Value (USD billion), By Country, 2024 & 2032
  • Figure 19: North America Prostate Cancer Therapeutics Market Value Share (%), By Country, 2024
  • Figure 20: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 21: Europe Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024
  • Figure 22: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 23: Europe Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024
  • Figure 24: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032
  • Figure 25: Europe Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024
  • Figure 26: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2024 & 2032
  • Figure 27: Europe Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2024
  • Figure 28: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 29: Europe Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 30: Europe Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 31: Europe Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 32: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 33: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024
  • Figure 34: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 35: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024
  • Figure 36: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion),by Therapy, 2024 & 2032
  • Figure 37: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024
  • Figure 38: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2024 & 2032
  • Figure 39: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2024
  • Figure 40: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 41: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 42: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 43: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 44: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 45: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024
  • Figure 46: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 47: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024
  • Figure 48: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032
  • Figure 49: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024
  • Figure 50: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2024 & 2032
  • Figure 51: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2024
  • Figure 52: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 53: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 54: Latin America Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 55: Latin America Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 56: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 57: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024
  • Figure 58: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 59: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024
  • Figure 60: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032
  • Figure 61: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024
  • Figure 62: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2024 & 2032
  • Figure 63: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2024
  • Figure 64: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 65: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 66: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 67: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 68: Global Prostate Cancer Therapeutics Market Share (%), By Company, 2024